GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
Author(s) -
Angela Stoddart,
Megan E. McNerney,
Elizabeth T. Bartom,
Rachel J. Bergerson,
David J. Young,
Zhijian Qian,
Jianghong Wang,
Anthony A. Fernald,
Elizabeth M. Davis,
Richard A. Larson,
K White,
Michelle M. Le Beau
Publication year - 2011
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2011.019
Subject(s) - medicine , myeloid , radiation therapy , haematopoiesis , progenitor cell , disease , targeted therapy , stem cell , cancer research , bioinformatics , genetics , pathology , biology , cancer
Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell. The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective. Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete. Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom